July 12 (Reuters) - CSL Ltd CSL.AX :
* Says new data demonstrate prophylactic treatment with idelvion reduces bleed frequency
* Says data shows idelvion has potential to positively impact patients with haemophilia B
* CSL - additional data shows idelvion prophylaxis regimens result in high rates of compliance, reduced consumption compared with previous fix
* CSL Ltd - additional data shows that idelvion prophylaxis regimens result in improvement in paediatric health-related quality of life Source text for Eikon: ID:nPn6LKNK9a Further company coverage: CSL.AX